A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

219

Participants

Timeline

Start Date

October 8, 2017

Primary Completion Date

October 27, 2020

Study Completion Date

July 28, 2023

Conditions
Carcinoma, Transitional CellUrinary Bladder NeoplasmsUrologic NeoplasmsRenal Pelvis NeoplasmsUrothelial CancerUreteral NeoplasmsUrethral Neoplasms
Interventions
DRUG

Enfortumab vedotin

Intravenous (IV) infusion on days 1, 8 and 15 every 28 days

Trial Locations (81)

10016

New York University (NYU) Cancer Institute, New York

10029

Mount Sinai Medical Center, New York

10032

Columbia University Medical Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

12208

New York Oncology Hematology, P.C., Albany

14642

James P. Wilmot Cancer Center / University of Rochester Medical Center, Rochester

15232

University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center, Pittsburgh

19107

Thomas Jefferson University, Philadelphia

20850

Maryland Oncology Hematology, P.A., Rockville

21231

Johns Hopkins Medical Center, Baltimore

22031

Virginia Cancer Specialists, PC, Fairfax

22903

University of Virginia, Charlottesville

23502

Virginia Oncology Associates, Norfolk

27710

Duke University Medical Center, Durham

29615

Prisma Health, Greenville

30912

Augusta University, Augusta

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

34474

Ocala Oncology Center, Ocala

37204

Vanderbilt University Medical Center, Nashville

40207

Norton Cancer Institute, St. Matthews Campus, Louisville

43210

James Cancer Hospital / Ohio State University, Columbus

44195

Cleveland Clinic, Cleveland

48201

Karmanos Cancer Institute / Wayne State University, Detroit

63110

Washington University in St Louis, St Louis

75246

Texas Oncology - Baylor Sammons Cancer Center, Dallas

77030

Houston Methodist Cancer Center, Houston

78731

Texas Oncology - Austin Central, Austin

80012

Rocky Mountain Cancer Centers - Aurora, Aurora

85054

Mayo Clinic Arizona, Phoenix

85395

Arizona Oncology Associates, PC - HAL, Goodyear

85710

Arizona Oncology Associates, PC - HOPE, Tucson

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

90033

Keck Medical Center / University of Southern California, Los Angeles

92663

Keck Medical Center / Newport Beach, Newport Beach

92868

Chao Family Comprehensive Cancer Center University of California Irvine, Orange

University of California Irvine - Newport, Orange

94080

Kaiser Permanente South San Francisco, South San Francisco

94115

Kaiser Permanente San Francisco, San Francisco

94577

Kaiser Permanente San Leandro, San Leandro

94589

Kaiser Permanente Medical Center Northern California, Vallejo

94596

Kaiser Permanente Walnut Creek, Walnut Creek

94611

Kaiser Permanente Oakland, Oakland

95051

Kaiser Permanente Santa Clara, Santa Clara

95119

Kaiser Permanente San Jose, San Jose

95661

Kaiser Permanente Roseville, Roseville

95817

University of California Davis, Sacramento

95825

Kaiser Permanente Sacramento, Sacramento

97223

Northwest Cancer Specialists, P.C., Tigard

99503

Alaska Urological Institute, Anchorage

06520

Yale Cancer Center, New Haven

60637-1470

University of Chicago Medical Center, Chicago

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

98109-1023

Seattle Cancer Care Alliance / University of Washington, Seattle

Unknown

Site FR33001, Villejuif-Cedex-France

Site DE49004, Münster

Site DE49001, Tübingen

Site IT39001, Milan

Site IT39003, Terni

Site JP81001, Hirosaki

Site JP81004, Tsukuba

Site JP81002, Morioka

Site JP81003, Nigata

Site JP81008, Sayama

Site JP81006, Shinjuku-ku

Site JP81009, Ube

Site JP81005, Chiba

Site JP81011, Fukuoka

Site JP81012, Fukuoka

Site JP81007, Osaka

Site JP81010, Tokushima

Site NL31001, Amsterdam

Site KR82005, Daejeon

Site KR82003, Seongnam-si

Site KR82001, Seoul

Site KR82002, Seoul

Site KR82004, Seoul

Site ES34002, Barcelona

Site ES34005, Barcelona

Site ES34003, Santander

Site ES34004, Seville

Sponsors
All Listed Sponsors
collaborator

Seagen Inc.

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY